Open AccessPD-L1 Expression Promotes Epithelial to Mesenchymal Transition in Human Esophageal Cancer
Author(s) -
Lujun Chen,
Yuqi Xiong,
Jing Li,
Xiao Zheng,
Qi Zhou,
Abbey Turner,
Changping Wu,
Binfeng Lu,
Jingting Jiang
Publication year - 2017
Publication title -
cellular physiology and biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.486
H-Index - 87
eISSN - 1421-9778
pISSN - 1015-8987
DOI - 10.1159/000480000
Subject(s) - cancer research , epithelial–mesenchymal transition , cancer , esophageal cancer , cancer cell , tumor microenvironment , pd l1 , immunotherapy , immune checkpoint , cancer immunotherapy , immunohistochemistry , biology , medicine , metastasis , pathology
PD-L1 (Programmed cell death 1 ligand 1, PD-L1), an essential immune checkpoint molecule in the tumor microenvironment, is an important target for cancer immunotherapy. We have previously reported that its expression in human gastric and esophageal cancer tissues is significantly associated with cancer progression and patients' postoperative prognoses. Its expression in cancer cells is well known to inhibit the T cell-mediated anti-tumor response, and this mechanism of action has been targeted for cancer immunotherapy. As of now, the autonomous effect of PD-L1 on cancer cells is not well understood, thus our present study aimed to examine the role of PD-L1 intervention in cellular biological functions, especially epithelial to mesenchymal transition (EMT), of the human esophageal cancer cell line, Eca-109 cells.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom